Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
Ascletis Pharma Inc. has initiated two Phase I studies in the U.S. for obesity treatment: ASC36, a once-monthly to once-quarterly amylin receptor peptide agonist, and ASC36_35FDC, a once-monthly fixed dose combination of